UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
human necessities (6) 6
hygiene (6) 6
medical or veterinary science (6) 6
preparations for medical, dental, or toilet purposes (6) 6
specific therapeutic activity of chemical compounds ormedicinal preparations (6) 6
cardiovascular (5) 5
humans (5) 5
life sciences & biomedicine (5) 5
science & technology (5) 5
cholesterol, ldl - blood (4) 4
double-blind method (4) 4
female (4) 4
male (4) 4
middle aged (4) 4
statins (4) 4
abridged index medicus (3) 3
aged (3) 3
alirocumab (3) 3
analysis (3) 3
antibodies (3) 3
cardiovascular disease (3) 3
cholesterol (3) 3
follow-up studies (3) 3
hypercholesterolemia (3) 3
immunoglobulins (3) 3
injections, subcutaneous (3) 3
low density lipoprotein (3) 3
low density lipoproteins (3) 3
treatment outcome (3) 3
acute coronary syndromes (2) 2
antibodies, monoclonal (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal - therapeutic use (2) 2
anticholesteremic agents (2) 2
cardiac & cardiovascular systems (2) 2
cardiovascular system & cardiology (2) 2
care and treatment (2) 2
clinical trial (2) 2
diabetes (2) 2
drug therapy (2) 2
drug therapy, combination (2) 2
hypercholesterolemia - blood (2) 2
hypercholesterolemia - drug therapy (2) 2
hypolipidemic agents - therapeutic use (2) 2
internal medicine (2) 2
lipoproteins (2) 2
low-density lipoprotein cholesterol (2) 2
medical research (2) 2
medicine, experimental (2) 2
proprotein convertase 9 - antagonists & inhibitors (2) 2
viral antibodies (2) 2
317 pharmacy (1) 1
[ sdv.mhep.csc ] life sciences [q-bio]/human health and pathology/cardiology and cardiovascular system (1) 1
[sdv.mhep.csc]life sciences [q-bio]/human health and pathology/cardiology and cardiovascular system (1) 1
acute coronary syndrome (1) 1
acute coronary syndrome - blood (1) 1
acute coronary syndrome - drug therapy (1) 1
acute coronary syndrome - mortality (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibodies, monoclonal, humanized (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies; humans; antibodies, monoclonal; anticholesteremic agents; medicine (1) 1
anticholesteremic agents - administration & dosage (1) 1
anticholesteremic agents - therapeutic use (1) 1
antilipemic agents (1) 1
biological products (1) 1
biopharmaceutics (1) 1
calculating (1) 1
cardiac patients (1) 1
cardiology and cardiovascular medicine (1) 1
cardiology and cardiovascular system (1) 1
cardiovascular agents (1) 1
cardiovascular diseases - complications (1) 1
cardiovascular diseases - epidemiology (1) 1
cardiovascular diseases - prevention & control (1) 1
cardiovascular risk (1) 1
cholesterol, ldl (1) 1
cholesterol, ldl - antagonists & inhibitors (1) 1
cholesterol, ldl - drug effects (1) 1
clinical decision-making (1) 1
clinical studies (1) 1
clinical trial, phase iii (1) 1
clinical trials (1) 1
cohort studies (1) 1
combined modality therapy (1) 1
combined modality therapy - adverse effects (1) 1
complications and side effects (1) 1
computing (1) 1
coronary disease (1) 1
coronary disease - blood (1) 1
coronary disease - prevention & control (1) 1
cost-effectiveness (1) 1
counting (1) 1
data processing systems or methods, specially adapted foradministrative, commercial, financial, managerial, supervisoryor forecasting purposes (1) 1
decision making (1) 1
diabetes complications - blood (1) 1
diabetes complications - drug therapy (1) 1
diabetes complications - prevention & control (1) 1
diabetes complications - therapy (1) 1
diet therapy (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The American journal of cardiology, ISSN 0002-9149, 09/2017, Volume 120, Issue 6, pp. 931 - 939
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2015, Volume 65, Issue 10, pp. A1370 - A1370
Conclusion: CHOICE II will provide novel ALI efficacy and safety data (including 150 mg Q4W dosing) on background FENO, EZE or diet. Since ~90% pts enrolled... 
Medicine, Experimental | Medical research | Care and treatment | Hypercholesterolemia | Statins | Drug therapy | Cardiovascular disease
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2017, Volume 376, Issue 16, pp. 1589 - 1590
In 10 clinical trials involving 4747 patients, among those who received the PCSK9 inhibitor alirocumab, antidrug antibodies developed in 5.1%, although no... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antibodies | Anticholesteremic Agents | Antibodies, Monoclonal | Humans | Clinical trials | Lipoproteins (low density) | Immunoglobulins | Low density lipoprotein | Cholesterol | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 07/2017, Volume 19, Issue 7, pp. 989 - 996
Aim This sub‐analysis of the ODYSSEY COMBO II study compared the effects of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in... 
clinical trial | cardiovascular disease | type 1 diabetes | type 2 diabetes | dyslipidaemia | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hyperlipidemias - blood | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Diabetes Complications - therapy | Serine Proteinase Inhibitors - therapeutic use | Antibodies, Monoclonal, Humanized | Cardiovascular Diseases - complications | Drug Therapy, Combination - adverse effects | Serine Proteinase Inhibitors - adverse effects | Healthy Lifestyle | Injections, Subcutaneous | Cardiovascular Diseases - epidemiology | Cholesterol, LDL - blood | Female | Hyperlipidemias - therapy | Hyperlipidemias - complications | Diabetes Complications - prevention & control | Hypolipidemic Agents - adverse effects | Serine Proteinase Inhibitors - administration & dosage | Double-Blind Method | Drug Administration Schedule | Hyperlipidemias - drug therapy | Risk Factors | Diabetes Complications - drug therapy | Combined Modality Therapy - adverse effects | Diabetes Complications - blood | Proprotein Convertase 9 - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Hypolipidemic Agents - administration & dosage | Aged | Hypolipidemic Agents - therapeutic use | Cohort Studies | Type 2 diabetes | Complications and side effects | Medical research | Care and treatment | Type 1 diabetes | Analysis | Low density lipoproteins | Cardiac patients | Medicine, Experimental | Statins | Cardiovascular agents | Low density lipoprotein | Diabetes | Index Medicus | Original
Journal Article
Journal of the American Heart Association, ISSN 2047-9980, 2016, Volume 5, Issue 9, p. n/a
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2016, Volume 67, Issue 13, pp. 1863 - 1863
Conclusions Data do not suggest a relationship between ADA or NAb and ALI LDL-C lowering efficacy or safety, with the exception of increased injection site... 
Cardiovascular | Internal Medicine | Viral antibodies | Antibodies | Low density lipoproteins | Biopharmaceutics | Drug dosages | Immunoglobulins
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 07/2017, Volume 19, Issue 7, pp. 989 - 996
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 02/2019, Volume 73, Issue 4, pp. 387 - 396
The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with... 
alirocumab | total events | acute coronary syndrome
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 11/2018, Volume 138, Issue Suppl_1 Suppl 1, pp. A13393 - A13393
IntroductionIn ODYSSEY OUTCOMES, first occurrence of coronary heart disease (CHD) death, myocardial infarction (MI), fatal/nonfatal ischemic stroke, or... 
Journal Article
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 11/2016, Volume 134, Issue Suppl_1 Suppl 1, pp. A16611 - A16611
AimODYSSEY CHOICE I (NCT01926782) evaluated 300 mg alirocumab (ALI) every 4 weeks (Q4W) for 48 weeks in patients with hypercholesterolemia at moderate to... 
Journal Article
Journal of clinical lipidology, ISSN 1933-2874, 11/2019, Volume 13, Issue 6, pp. 979 - 988.e10
Alirocumab is a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9). Changes in PCSK9, alirocumab, and low-density lipoprotein... 
PCSK9 | Clinical trial | Monoclonal antibody | Cardiovascular | Low-density lipoprotein cholesterol | Pharmacokinetic | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Index Medicus
Journal Article
Journal of the American Heart Association, ISSN 2047-9980, 09/2016, Volume 5, Issue 9
BACKGROUND: The PCSK9 antibody alirocumab (75 mg every 2 weeks; Q2W) as monotherapy reduced low-density lipoprotein-cholesterol (LDL-C) levels by 47%. Because... 
Journal Article
Journal Article
Journal of clinical lipidology, ISSN 1933-2874, 2013, Volume 7, Issue 3, pp. 279 - 279
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.